ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway
International Journal of Nanomedicine · 2026-02 · Volume 21 · 1-18
DOI: 10.2147/ijn.s558115 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-02. Verfasst von Yanmei Qiu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Institute of Innovation for Combined Medicine and Engineering (NIIME), The Affiliated LiHuili Hospital of Ningbo University, Ningbo, Zhejiang,…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Selenium, Reactive Oxygen Species, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Current cervical cancer treatments have yet to realize significant advances in patient quality of life. To overcome the challenges of off-target toxicity and inefficient delivery, we developed targeted ROS-responsive selenium nanoparticles, based on selenium's anticancer properties.
Methods
FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models.
Results
Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity.
Conclusion
This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ningbo Institute of Innovation for Combined Medicine and Engineering (NIIME), The Affiliated LiHuili Hospital of Ningbo University, Ningbo, Zhejiang, 315100, People's Republic of China.
- The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
- School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, Zhejiang, 311215, People's Republic of China.
- Department of Obstetrics and Gynecology, LiHuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, 315040, People's Republic of China.
ORCID-Profile: Yanmei Qiu, Chongke Hu, Xiaoping Huang, Lingling Zhao, Fei Guo
Zitieren
APA
Qiu, Y., Hu, C., Zhao, S., Chen, D., Shen, J., Dai, F., Ban, M., Ma, Y., Weng, J., Huang, X., Zhu, Y., Zhao, L., & Guo, F. (2026). ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway. International Journal of Nanomedicine, Volume 21, 1-18. https://doi.org/10.2147/ijn.s558115
Vancouver
Qiu Y, Hu C, Zhao S, Chen D, Shen J, Dai F, et al. ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway. International Journal of Nanomedicine. 2026;Volume 21:1-18. doi:10.2147/ijn.s558115
BibTeX
@article{Qiu2026,
author = {Qiu, Yanmei and Hu, Chongke and Zhao, Sifang and Chen, Dezhi and Shen, Jiaying and Dai, Fanjia and Ban, Mengxin and Ma, Yimin and Weng, Jingjing and Huang, Xiaoping and Zhu, Yingying and Zhao, Lingling and Guo, Fei},
title = {ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--18},
doi = {10.2147/ijn.s558115}
}
EUVIMED